Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2026 Earnings Call Transcript
Operator: Hello, everyone. Thank you for joining us, and welcome to Ligand's First Quarter 2026 Earnings Call.
Posts Tagged ‘NASDAQ:LGND’
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript August 7, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript May 8, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Aaron, and I will be your conference operator for today.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.
13 Most Promising Small-Cap Stocks According to Analysts
In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Danika and I'll be your conference operator today.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Brian, and I will be your conference operator today.
Top 12 Small-Cap Stocks With Highest Upside Potential
In this piece, we will take a look at the top 12 small-cap stocks with the highest upside potential.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kyla Baker and I will be your conference operator today.
10 Best Small-Cap Growth Stocks to Buy Now
Every day, countless stocks see their values rise and fall on the market.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2022 Earnings Call Transcript
Operator: Good evening. My name is Rob and I will be your conference operator today.
15 Most Volatile Stocks to Buy Now
Even though the United States stock market is inextricably linked to the US economy, there are increased fears that the factors contributing to the decline of both in the past...
Should You Consider Investing in Ligand Pharmaceuticals (LGND)?
Bumbershoot Holdings LP, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. Bumbershoot Holdings L.P.
Hedge Fund and Insider Trading News: Michael Burry, Chris Hohn, Fortress Investment Group, Magnetar Capital, Verde Asset Management, Lemelson Capital Management, Evli Factor Premia Fund, Renovacor Inc (RCOR), Assurant, Inc. (AIZ), and More
NEW YORK--(BUSINESS WIRE)-- Fortress Investment Group LLC (“Fortress”) was named the recipient of the inaugural “Diversity and Inclusion Achievement” award at the 2021...
Here’s Why Ligand Pharmaceuticals (LGND) Became Wasatch Global’s Q1 2021 Top Contributor
Wasatch Global Investors, an investment management firm, published its “Wasatch Core Growth Fund” first quarter 2021 investor letter – a copy of which can be downloaded ...
Is LGND A Good Stock To Buy According To Hedge Funds?
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Should I Avoid Ligand Pharmaceuticals Inc. (LGND)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Were Hedge Funds Right About Ligand Pharmaceuticals Inc. (LGND)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Fund and Insider Trading News: Kyle Bass, Steve Cohen, Cheyne Capital, Worm Capital, Broadcom Inc (AVGO), Ligand Pharmaceuticals Inc. (LGND), and More
Steve Cohen hasn’t given up on buying the New York Mets.
Hedge Funds Piling Into Ligand Pharmaceuticals Inc. (LGND) Again
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Are Betting On Ligand Pharmaceuticals Inc. (LGND)
We hate to say this but, we told you so.
Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy ?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great...
Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Hedge Fund and Insider Trading News: Michael Novogratz, David Tepper, Citadel, ValueAct Capital, Ligand Pharmaceuticals Inc. (LGND), Vaccinex Inc (VCNX), and More
Hedge fund manager turned cryptocurrency investor Michael Novogratz cautioned that the stock market is nearing the end of its historic rally.
Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?
How do we determine whether Ligand Pharmaceuticals Inc.
Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period.
Ligand Pharmaceuticals Inc. (LGND) Hedge Funds Are Snapping Up
Is Ligand Pharmaceuticals Inc.
Hedge Fund and Insider Trading News: Crispin Odey, Oaktree Capital Management, CBA Florida Inc (CBAI), GCP Applied Technologies Inc (GCP), FitLife Brands Inc (FTLF), and More
Hedge-fund manager Crispin Odey said underperforming banks are starting to resemble department stores that failed to reinvent themselves quickly enough to compete with online ...
Hedge Fund and Insider Trading News: Ray Dalio, Israel Englander, Heartland Express, Inc. (HTLD), Tandy Leather Factory, Inc. (TLF), Solaredge Technologies Inc (SEDG), and More
President Donald Trump's decision Thursday to cancel the Singapore summit with North Korea leader sent the price of gold higher as global investors sought safety.
Ligand Pharmaceuticals Inc. (LGND): Hedge Fund Sentiment Unchanged
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that...
Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?
The third-quarter stock market correction has turned out to resemble the situation observed during the Asian financial crisis of 1997.
Dorset Management Made a Bundle By Betting on Biotech and Energy; More Profits to Come?
David M. Knott’s Dorset Management seems to have had an excellent start to the year.
Apple Inc. (AAPL), Google Inc (GOOG), Ligand Pharmaceuticals Inc. (LGND): Blue Clay Capital’s Picks Destroyed Index Funds
Adam Wright and Gary Kohler’s Blue Clay Capital performed much better than Index Funds in the first quarter, as its 27 long positions in stocks with a market cap above $1.0 ...
Carl Wiese’s Grow Partners Top Picks in Q4
Carl Wiese founded Grow Partners in 2012. Wiese has more than 22 years of investment management experience.
Do Hedge Funds and Insiders Love Akorn, Inc. (AKRX)?
To many of your peers, hedge funds are viewed as useless, old investment tools of an era lost to time.
Hedge Funds Are Betting On Momenta Pharmaceuticals, Inc. (MNTA)
Now, according to many market players, hedge funds are assumed to be bloated, outdated investment tools of a period lost to current times.
Hi-Tech Pharmacal Co. (HITK): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
To the average investor, there are tons of gauges investors can use to monitor stocks. A duo of the best are hedge fund and insider trading activity.
This Metric Says You Are Smart to Buy Sagent Pharmaceuticals Inc (SGNT)
If you were to ask many of your fellow readers, hedge funds are seen as useless, old investment tools of a forgotten age.
Is Salix Pharmaceuticals, Ltd. (SLXP) Going to Burn These Hedge Funds?
In the 21st century investor’s toolkit, there are dozens of methods shareholders can use to monitor their holdings.
Do Hedge Funds and Insiders Love Mylan Inc. (MYL)?
To many investors, hedge funds are assumed to be overrated, old financial vehicles of an era lost to time.
Hedge Funds Are Crazy About Ligand Pharmaceuticals Inc. (LGND)
At the moment, there are dozens of methods investors can use to monitor the equity markets. Some of the most useful are hedge fund and insider trading interest.
Antares Pharma Inc (ATRS), ISIS Pharmaceuticals, Inc. (ISIS), Ligand Pharmaceuticals Inc. (LGND): 3 Pharma Stocks You Need to Watch for the Rest of 2013
It's hard to believe, but 2013 is already more than halfway over. This year has been a good one for many pharmaceutical stocks -- at least so far.
Hedge Fund Resource Center
